ANGO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
AngioDynamics Inc (ANGO) is a good buy for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. The stock shows positive momentum with bullish moving averages, recent FDA approvals acting as strong catalysts, and analysts maintaining a Buy rating with a $16 price target. Despite no significant trading signals or congress trading data, the positive sentiment and growth potential make it an attractive long-term investment.
The stock's technical indicators are moderately bullish. The moving averages (SMA_5 > SMA_20 > SMA_200) suggest upward momentum. RSI is neutral at 57.783, and the MACD is slightly negative but contracting, indicating a potential shift to positive momentum. Key resistance levels are at 12.422 and 12.641, while support levels are at 11.711 and 11.492.
FDA approval for the RELIEF study using NanoKnife technology to treat benign prostatic hyperplasia.
Analysts maintain a Buy rating with a $16 price target, citing improved growth prospects and raised guidance.
Bullish moving averages and positive pre-market and regular market price changes.
Post-market price decline of -0.91%.
MACD is still slightly negative, and no significant trading signals from Intellectia Proprietary Trading Signals.
No financial data available for analysis.
Analysts are positive on ANGO, with Freedom Broker initiating coverage with a Buy rating and a $16 price target. Canaccord also maintains a Buy rating, lowering the price target slightly to $16 but highlighting revenue beats and raised guidance.
